Clinical trials: Nonalcoholic Steatohepatitis
Non-alcoholic Fatty Liver Disease
Effect of Ginger Supplement on Non-alcoholic Fatty Liver
The hypothesis of this study was that ginger supplement consumption can be introduced as a new therapeutic strategy for non-alcoholic fatty liver disease through the improved body antioxidant activity, reduced levels of…
- Trial name
- NCT02535195
- Testing
- Ginger supplement
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Dr Azita Hekmatdoost
NAFLD, Cardiac Disease
Cardiac Dysfunction in Patients with Fatty Liver Disease
Cirrhotic cardiomyopathy is seen as a blunted contractile responsiveness to stress, and/or altered diastolic relaxation with electrophysiological abnormalities, in absence of known cardiac disease.
- Conditions
- NAFLD, Cardiac Disease, Fatty Liver, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- NCT06386094
- Testing
- Echocardiographic assessment
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
NAFLD, NASH - Nonalcoholic Steatohepatitis
A Self Selected Population Study of Undiagnosed NAFLD and NASH, Using an Echosens FibroScan, in at Risk Populations
Liver disease (NAFLD) and (NASH) are a rapidly increasing population health threat driven primarily by diet and lifestyle. Fibrotic liver disease, culminating in cirrhosis, is frequently asymptomatic so it is common for a patient…
- Conditions
- NAFLD, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver, Fatty Liver
- Trial name
- SUNN (NCT03726827)
- Testing
- Fibroscan screening
- Where
- United States
- Volunteers
- 1,006 people, healthy volunteers welcome
- Sponsor
- Fatty liver Foundation
NAFLD, NASH - Nonalcoholic Steatohepatitis
Safety and Tolerability of Novel Medical Nutrition Products for NAFLD Treatment
To the moment, only limited data are present on the efficacy of changes in diet composition of patients with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- 052920190055 (NCT04308980)
- Testing
- Specialized product for medical nutrition (SPP-1), individualized diet
- Where
- Russia
- Volunteers
- 45 people
- Sponsor
- Russian Academy of Medical Sciences
Non-Alcoholic Fatty Liver Disease, Cognitive Impairment
Cognitive Assessment and Brain Function Evaluation in Patients With Non-alcoholic Fatty Liver Disease
The purpose of this study is to explore the relationship between Non-alcoholic fatty liver disease and cognitive impairment and evaluate the effect of metabolic surgery or lifestyle intervention on cognition.
- Trial name
- NCT05563259
- Testing
- Cognitive assessment, functional magnetic resonance imaging
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Yan Bi
Non-Alcoholic Fatty Liver Disease, Chronic Liver Disease
Combination Diagnostic Strategies in NAFLD
Serial combination of biological and elastography tests is accurate to diagnosing advanced fibrosis in non-alcoholic fatty liver disease (NAFLD) patients.
- Trial name
- CombinationSSI (NCT04384159)
- Volunteers
- 577 people
- Sponsor
- University Hospital, Montpellier
Non-alcoholic Fatty Liver Disease NAFLD
Assessment of Tolerability of Specialized Food Products Made Out of Vegetable Protein and Their Influence on Lipid Profile in Patients With Non-alcoholic Fatty Liver Disease
To this single-centre randomized controlled comparative study it is planned to enroll 50 patients with non-alcoholic fatty liver disease. All these subjects will receive standard isocaloric diet for 14 days.
- Trial name
- NCT06727279
- Testing
- Specialized food - Plant-Based Meat Analog, standard isocalorie diet
- Volunteers
- 50 people
- Sponsor
- Federal State Budgetary Scientific Institution
Non-Alcoholic Fatty Liver Disease, Insulin Resistance
Effect of PNPLA3, TM6SF2 and MBOAT7 Genetic Variants on Non-alcoholic Fatty Liver Disease Therapeutic Outcome.
Patatin-like phospholipase domain-containing protein-3 (PNPLA3), the transmembrane 6 superfamily member 2 protein (TM6SF2) and membrane bound O-acyltransferase domain containing 7 (MBOAT7) genes are involved in non-alcoholic…
- Trial name
- NCT04640324
- Testing
- Nutraceutical therapy
- Where
- 3 sites in Italy
- Volunteers
- 92 people
- Sponsor
- University of Campania Luigi Vanvitelli
NAFLD, MASLD
NAFLD Clinical Care Pathway
Non-alcoholic fatty liver disease (NAFLD) is a new condition that has become the most common chronic liver disease in the world and a main cause of liver cirrhosis, liver failure and liver cancer.
- Trial name
- NCCP (NCT06671886)
- Testing
- E-trigger
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
NASH - Nonalcoholic Steatohepatitis, Insulin Sensitivity
Proof of Concept ELectro-Stimulation of Muscles to resolVe Insulin Resistance in NASH
Non-alcoholic steato-hepatitis (NASH) affects up to 3% of the population and leads to liver cirrhosis, hepatocellular carcinoma (HCC) and death. The only known treatment is weight loss and exercise.
- Trial name
- ELVIS (NCT03490370)
- Testing
- Electro-muscular stimulation using NeuroTrac MyoPlus 2/4
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- NHS Tayside
Chronic Liver Disease, NASH - Nonalcoholic Steatohepatitis
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects
A Phase 1a, Double Blind, Placebo-Controlled, Single-Center, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Volunteers
- Trial name
- NCT04146805
- Testing
- BLD-0409
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Blade Therapeutics
Non-alcoholic Steatohepatitis
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH).
- Trial name
- NCT05016882
- Testing
- NNC0194 0499 50 mg/mL, Semaglutide 3 mg/mL, NNC0174 0833 10 mg/mL
- Where
- 255 sites in United States, Australia and 22 more
- Volunteers
- 698 people
- Sponsor
- Novo Nordisk A/S
Fatty Liver Disease
Synbiotics Impact on Insulin and TNF-α in MAFLD: a Gut Microbiota Profile Analysis
Primary Objective: To analyze the effect of synbiotic supplementation on metabolic profile, insulin and TNF-α and gut microbiota changes in patients with Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD).
- Trial name
- NCT06585982
- Testing
- Treatment, Control
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Universitas Diponegoro
Morbid Obesity, NAFLD
Sleeve Gastrectomy in Adolescents With Complicated Morbid Obesity and NAFLD
Pediatric obesity has become a critical health problem worldwide, increasing the premature onset of obesity-related morbidities.
- Trial name
- NCT02564679
- Testing
- Laparoscopic Sleeve gastrectomy (LSG), Lifestyle Intervention
- Volunteers
- 40 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Heathy Participants
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants.
The study will evaluate the safety, tolerability, and the pharmacokinetics (PK) of AZD7503 following multiple subcutaneous doses in healthy Japanese participants.
- Trial name
- NCT06093542
- Testing
- AZD7053
- Where
- Japan
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Nonalcoholic Steatohepatitis (NASH)
The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects
This study is a safety, tolerability, and pharmacokinetics phase Ⅰstudy of HEC96719, in healthy subjects.This study is the healthy adult subjects single ascending-dose research
- Trial name
- NCT04194242
- Testing
- HEC96719 tablets
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Metabolic Syndrome X, Liver Diseases
Effects of Macronutrients on Hepatic Lipids, Plasma Triglycerides, and Insulin Sensitivity
The purpose of this study is to assess how the macronutrient composition of the diet effects lipid and glucose metabolism intrahepatic lipids insulin sensitivity in healthy lean subjects and in subjects with a high metabolic risk…
- Trial name
- MACRONUTR (NCT00523562)
- Testing
- diet intervention
- Where
- Switzerland
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of Lausanne
Obesity, NAFLD
The Impact of Bariatric Surgery on Non-alcoholic Fatty Liver Disease
Up to 300 million people have a BMI over 30kg/m2. Obesity is the cause of many serious diseases, such as type 2 diabetes, hypertension and NAFLD.
- Trial name
- NCT02828579
- Testing
- Bariatric surgery
- Volunteers
- 20 people
- Sponsor
- Jagiellonian University
Non-alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liver Disease (ALD)
Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients
The primary objective of the SOPRANO study is to compare two blood fibrosis tests, the eLIFT and the FibroMeter, for the screening of advanced liver fibrosis in patients with NAFLD and/or ALD from primary care centers.
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liver Disease (ALD), Liver Fibrosis
- Trial name
- SOPRANO (NCT05699018)
- Testing
- eLIFT
- Where
- 13 sites in France
- Volunteers
- 1,788 people
- Sponsor
- University Hospital, Angers
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
The aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive imaging and serum-based methods with the goal of…
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fibrosis, Liver, Type 1 Diabetes
- Trial name
- NCT04595474
- Testing
- Transient Elastography
- Where
- United States
- Volunteers
- 533 people
- Sponsor
- Joslin Diabetes Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.